CN114286864B - 慢病毒载体产生方法及构建体 - Google Patents

慢病毒载体产生方法及构建体

Info

Publication number
CN114286864B
CN114286864B CN202080059158.XA CN202080059158A CN114286864B CN 114286864 B CN114286864 B CN 114286864B CN 202080059158 A CN202080059158 A CN 202080059158A CN 114286864 B CN114286864 B CN 114286864B
Authority
CN
China
Prior art keywords
gene
lentiviral
promoter
vector
transposon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080059158.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114286864A (zh
Inventor
Y·申
A·赛斯
顾炳南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Walkersville Inc
Original Assignee
Lonza Walkersville Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Walkersville Inc filed Critical Lonza Walkersville Inc
Publication of CN114286864A publication Critical patent/CN114286864A/zh
Application granted granted Critical
Publication of CN114286864B publication Critical patent/CN114286864B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8673—Special methods for packaging systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8676—Special methods for targeting systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080059158.XA 2019-08-23 2020-08-24 慢病毒载体产生方法及构建体 Active CN114286864B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962890904P 2019-08-23 2019-08-23
US62/890,904 2019-08-23
PCT/US2020/047650 WO2021041322A1 (en) 2019-08-23 2020-08-24 Methods and constructs for production of lentiviral vector

Publications (2)

Publication Number Publication Date
CN114286864A CN114286864A (zh) 2022-04-05
CN114286864B true CN114286864B (zh) 2025-08-15

Family

ID=74679320

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080059158.XA Active CN114286864B (zh) 2019-08-23 2020-08-24 慢病毒载体产生方法及构建体

Country Status (7)

Country Link
US (3) US12037599B2 (enExample)
EP (1) EP4017987A4 (enExample)
JP (2) JP2022551219A (enExample)
KR (1) KR20220047635A (enExample)
CN (1) CN114286864B (enExample)
IL (1) IL290820A (enExample)
WO (1) WO2021041322A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192193A1 (en) * 2021-03-09 2022-09-15 The Board Of Regents Of The University Of Texas System Methods and compositions for mutagenesis screening in mammalian cells
CA3217480A1 (en) * 2021-04-23 2022-10-27 Asimov Inc. Stable production systems for lentiviral vector production
KR20240099439A (ko) 2021-11-09 2024-06-28 프라운호퍼 게젤샤프트 쭈르 푀르데룽 데어 안겐반텐 포르슝 에. 베. 코알라 레트로바이러스 외피 당단백질 및 그 용도
CN121127601A (zh) * 2023-05-12 2025-12-12 隆萨生物制剂股份有限公司 使用转座酶进行混合瞬时转染以用于高产率产物生产

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144893A1 (en) * 2016-02-26 2017-08-31 Ucl Business Plc Retrovirus packaging cell

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
US10087463B2 (en) 2000-10-31 2018-10-02 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
WO2002092134A1 (en) * 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
US20090042297A1 (en) * 2007-06-01 2009-02-12 George Jr Alfred L Piggybac transposon-based vectors and methods of nucleic acid integration
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
WO2011097447A2 (en) 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus
WO2012028681A1 (en) 2010-09-02 2012-03-08 Molmed Spa Stable production of lentiviral vectors
CA2776577C (en) 2010-10-05 2021-03-30 Bayer Cropscience Lp A system and method establishing an agricultural pedigree for at least one agricultural product
WO2013076309A1 (en) 2011-11-24 2013-05-30 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
PT2790737T (pt) 2011-12-12 2019-02-28 Childrens Hospital Philadelphia Sistema de produção de vetores lentivirais a grande escala comercial e vetores produzidos pelo mesmo
PT2970920T (pt) 2013-03-15 2018-07-30 Childrens Hospital Philadelphia Processo de fabrico escalável para produzir vetores lentivirais recombinantes em sistema de cultura de células de suspensão livres de soro
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201417042D0 (en) 2014-09-29 2014-11-12 Fkd Therapies Oy Method
US20160267432A1 (en) 2015-03-13 2016-09-15 GeoPRI, LLC Systems and methods for tracking an individual unit
US20160350715A1 (en) 2015-05-29 2016-12-01 Eugenio Minvielle Nutrition Based Food System and Method
FR3044016A1 (fr) * 2015-11-24 2017-05-26 Glaxosmithkline Ip Dev Ltd Lignees cellulaires stables pour la production retrovirale
GB201603372D0 (en) * 2016-02-26 2016-04-13 Ucl Business Plc Cell
US10699284B2 (en) 2016-08-10 2020-06-30 Label Insight, Inc. Information management system for product ingredients to fill gaps in the market and to determine proper attribution
GB201705927D0 (en) 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
JP7598864B2 (ja) 2018-12-21 2024-12-12 ロンザ ウォーカーズヴィル，インコーポレーテッド ウイルスベクターの自動産生方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017144893A1 (en) * 2016-02-26 2017-08-31 Ucl Business Plc Retrovirus packaging cell

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lentiviral vector packaging cell line development using genome editing to target optimal loci discovered by high- throughput DNA barcoding;Alberto Molina Gil;A thesis submitted for the degree of Doctor of Philosophy 2017;20170101;全文 *

Also Published As

Publication number Publication date
US12391960B2 (en) 2025-08-19
IL290820A (en) 2022-04-01
US20240336936A1 (en) 2024-10-10
US12037599B2 (en) 2024-07-16
WO2021041322A1 (en) 2021-03-04
EP4017987A1 (en) 2022-06-29
JP2025148329A (ja) 2025-10-07
US20250263749A1 (en) 2025-08-21
CN114286864A (zh) 2022-04-05
US20210062220A1 (en) 2021-03-04
EP4017987A4 (en) 2023-10-04
JP2022551219A (ja) 2022-12-08
KR20220047635A (ko) 2022-04-18

Similar Documents

Publication Publication Date Title
US12391960B2 (en) Methods and constructs for production of lentiviral vector
Chen et al. Rapid lentiviral vector producer cell line generation using a single DNA construct
JP7469280B2 (ja) レンチウイルスベクターのバイオ生産法
JP7672114B2 (ja) 安定したレンチウイルスパッケージング細胞株およびその作成方法
JP7787064B2 (ja) レンチウイルスベクターの製造の増強
Sparacio et al. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors
JP2023516493A (ja) レンチウイルスベクター
JP2023513303A (ja) レンチウイルスベクターの製造
CN110520535A (zh) 用于逆转录病毒产生的稳定细胞系
US12398404B2 (en) Methods and constructs for transient production of lentiviral vector
CN122012625A (zh) 病毒载体生产
US20250122528A1 (en) Lentiviral vector
GB2538324A (en) Packaging cell line for retroviral production
GB2538321A (en) Artificial chromosome for retroviral production
HK40063602A (en) Methods and constructs for production of lentiviral vector
HK40063602B (en) Methods and constructs for production of lentiviral vector
JP2024514961A (ja) レンチウイルスベクター産生のための安定な産生系
HK40069471A (en) Methods and constructs for transient production of lentiviral vector
Schmidhofer Two novel systems for defined expression levels of mCherry protein
Hüllen Development and implementation of a genome-wide CRISPR/Cas9 screen for identification of cellular factors affecting recombinant adeno-associated virus (rAAV) production
CN117677706A (zh) 慢病毒载体
JP2023551397A (ja) ポリマー／核酸複合体の溶液の調製

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063602

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant